PI3Ka/mTOR inhibitor PKI-179
Term · Oncology and biomedicine · MLC-T-ONC-016040
A second generation, small-molecule mimetic of ATP that targets the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. PKI-179 selectively inhibits mTOR and phosphoinositide-3-kinase (PI3K) alpha. By inhibiting the PI3K/mTOR signaling pathway, this agent may inhibit tumor cell proliferation and survival.
| Identifier | MLC-T-ONC-016040 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016040",
"term": "PI3Ka/mTOR inhibitor PKI-179",
"field": "Oncology and biomedicine",
"definition": "A second generation, small-molecule mimetic of ATP that targets the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. PKI-179 selectively inhibits mTOR and phosphoinositide-3-kinase (PI3K) alpha. By inhibiting the PI3K/mTOR signaling pathway, this agent may inhibit tumor cell proliferation and survival.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/pi3ka-mtor-inhibitor-pki-179/"
}
Record 13,204 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.